Abstract

Compounding with Beta-1, 3-D-Glucan

Author(s): Keller Ted

Issue: Sep/Oct 2000 - Compounding for Immune System Disorders

Page(s): 342

Download in electronic PDF format for $75

Abstract

Beta-1,3-D-glucan, a homopolymer of glucose, is a brown powder consisting of beta-1,3-linked glucopyranose polymers, which are insoluble molecules in all solvents. In this article, various therapeutic applications of beta-1,3-D-glucan and its effect on the role of the macrophage in immune system functioning are presented. The author focuses on infectious diseases; allergy and breathing disorders; neoplastic disease and the side effects of treatment; diabetes, hypertension, cholesterol and liver disease; autoimmune disorders; dermatologic applications and additional benefits of treatment. She also provides four very brief case reports. She concludes that beta-1,3-D-glucan is a powerful adjunct to the treatment of several disorders and should be included in every compounding practice. Its disadvantage is that, if treatment fails, the expense of therapy has been wasted; however, therapeutic failures are infrequent.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Sep/Oct 2000 Pg. 342	Compounding with Beta-1, 3-D-Glucan Author(s): Keller Ted
Jul/Aug 2003 Pg. 288-291	Basics of Compounding for Raynaud's Disease Author(s): Glasnapp Andrew
May/Jun 2020 Pg. 194-197	Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality Author(s): Hagan John C III, Everett Eric, Chamberlain Tyler
Sep/Oct 2022 Pg. 364-368	A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans Author(s): Riepl Mike
May/Jun 2003 Pg. 188-191	Treating Canine Hepatic Disease Author(s): Davidson Gigi S
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
Nov/Dec 2007 Pg. 520-524	Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration Author(s): Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2011 Pg. 458-463	Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers Author(s): Zur Eyal
Jul/Aug 2016 Pg. 328-332	Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures Author(s): Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Nov/Dec 2011 Pg. 450-457	Compounding for Treatment of Equine Infectious Diseases: An Overview Author(s): Bramwell Bethany L
Jul/Aug 2004 Pg. 269-274	Current Topical Treatments in Wound Healing - Part 1 Author(s): Helmke Christopher D
Mar/Apr 2024 Pg. 129	Addendum to Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine A New Therapeutic Modality Author(s):
Sep/Oct 2012 Pg. 420	Esmolol Hydrochloride 10-mg/mL Injection Author(s): Allen Loyd V Jr
Sep/Oct 2007 Pg. 384-388	Equine Cushing's Disease: A Clinical Update Author(s): Bliss George
Jul/Aug 2022 Pg. 293-296	Compounding for Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases Author(s): Harrington Amy, Williams LaVonn
Nov/Dec 2021 Pg. 503	Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
May/Jun 2004 Pg. 206-209	Basics of Compounding for Cold Sores or Fever Blisters Author(s): Allen Loyd V Jr
May/Jun 2003 Pg. 170-174	Five Compounds for Treating Diabetes-Related Conditions Author(s): Meece Jerry
Jan/Feb 2014 Pg. 6-12	The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013 Author(s): Lutz Eugene, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
Nov/Dec 2022 Pg. 446-466	Compounding with Biotechnology Products, Part 2: Product-specific Considerations Author(s): Allen Loyd V Jr